899 related articles for article (PubMed ID: 25733246)
1. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D
Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246
[TBL] [Abstract][Full Text] [Related]
2. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H
Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208
[TBL] [Abstract][Full Text] [Related]
3. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR
Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
Rigby W; Tony HP; Oelke K; Combe B; Laster A; von Muhlen CA; Fisheleva E; Martin C; Travers H; Dummer W
Arthritis Rheum; 2012 Feb; 64(2):350-9. PubMed ID: 21905001
[TBL] [Abstract][Full Text] [Related]
5. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
6. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
[TBL] [Abstract][Full Text] [Related]
7. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR
RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928
[TBL] [Abstract][Full Text] [Related]
9. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
[TBL] [Abstract][Full Text] [Related]
11. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
13. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P
Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593
[TBL] [Abstract][Full Text] [Related]
16. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.
Yellin M; Paliienko I; Balanescu A; Ter-Vartanian S; Tseluyko V; Xu LA; Tao X; Cardarelli PM; Leblanc H; Nichol G; Ancuta C; Chirieac R; Luo A
Arthritis Rheum; 2012 Jun; 64(6):1730-9. PubMed ID: 22147649
[TBL] [Abstract][Full Text] [Related]
17. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
[TBL] [Abstract][Full Text] [Related]
18. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
[TBL] [Abstract][Full Text] [Related]
20. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD
Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
